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Background: The thrombin generation assay (TG) is a promising approach to measure
the degree of anticoagulation in patients treated with direct oral anticoagulants (DOAC).
A strong association with plasma drug concentrations would be a meaningful argument
for the potential use to monitor DOAC.
Objectives: We aimed to study the correlation of TG with rivaroxaban, apixaban, and
edoxaban drug concentrations in a large, prospective multicenter cross-sectional study.
Methods: Five-hundred and fifty-nine patients were included in nine tertiary hospitals.
The Technothrombin® TG was conducted in addition to an anti-Xa assay; LC-MS/MS
was performed as the reference standard.
Results: Correlation (rs) between thrombin generation measurements and drug
concentrations was −0.72 for peak thrombin generation (95% confidence interval, CI,
−0.77, −0.66), −0.55 for area under the curve (AUC; 95% CI −0.61, −0.48), and 0.80
for lag time (95% CI 0.75, 0.84). In contrast, rs was 0.96 with results of the anti-Xa
activity (95% CI 0.95–0.97). Sensitivity with regard to the clinically relevant cut-off value
of 50 µgL−1 was 49% in case of peak thrombin generation (95% CI, 44, 55), 29% in
case of AUC (95% CI, 24, 34), and 64% in case of lag time (95% CI, 58, 69). Sensitivity
of the anti-Xa assay was 95% (95% CI, 92, 97).
Conclusions: The correlation of thrombin generation measurements with DOAC drug
concentrations was weak, and clinically relevant drug levels were not predicted correctly.
Our results do not support an application of TG in the monitoring of DOAC.
Keywords: diagnostic accuracy, thrombin generation assay, anti-Xa assay, laboratory monitoring, rivaroxaban,
apixaban, edoxaban, direct oral anticoagulants
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GRAPHICAL ABSTRACT | Automated thrombin generation assay for rivaroxaban, apixaban, and edoxaban measurements.
INTRODUCTION
Direct oral anticoagulants (DOAC), including the anti-Xa
inhibitors rivaroxaban, apixaban, and edoxaban, have simplified
and improved health care in many patients worldwide (1).
However, whether or not drug monitoring would improve
patient outcomes remains unclear. Vitamin K antagonists (VKA)
and unfractionated heparin have been successfully applied for
decades, and treatment without monitoring would not have
been conceivable (2). Low molecular weight heparins (LMWH),
which share some similarities in the mechanism of action with
anti-Xa inhibitors, are applied using weight-adapted dosages
without the need for regular monitoring (3). Indeed, various
arguments for the monitoring of DOAC appear (4). First, an
association between drug exposure and bleeding events was
observed in some studies (5) and between trough concentrations
and thromboembolic events such as strokes in other studies (6, 7).
Second, several clinical factors (e.g., renal failure, liver failure, age
> 75 years) and several drug interactions (e.g., P-glycoprotein
and CYP3A4-modulating substances) significantly affect drug
concentrations (8–12). Third, a number of observational studies
observed a relevant inter-individual variation of the drug
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concentration (13–15). Other authors even summarized previous
data to suggest an optimal risk-benefit range pointing to
a potential target range based on drug concentrations (16).
However, the optimal laboratory assay to be used for monitoring
of DOAC is to be determined.
Different laboratory tests are being used to measure DOAC
drug concentrations in special clinical situations such as major
bleeding, urgent surgery, or suspected accumulation (17, 18).
The anti-Xa inhibitors rivaroxaban, apixaban, and edoxaban can
be determined using chromogenic anti-Xa assays (19). These
tests, which are successfully used to determine unfractionated
and low molecular weight heparins, were further developed
and successfully studied in various evaluation studies (15, 20).
Routine coagulation tests such as prothrombin time are not
sensitive to detect clinically relevant concentrations of anti-
Xa inhibitors (21). The thrombin inhibitor dabigatran can be
captured using the thrombin time, an extremely sensitive routine
coagulation test available in many institutions (18). Diluted
thrombin times have been developed to measure dabigatran drug
concentrations (22, 23). Besides, the ecarin clotting time can be
utilized to estimate dabigatran drug concentrations (19, 22).
The thrombin generation assay (TG) is regarded as a
promising approach for monitoring DOAC anticoagulant
activity (24). It can record the amount and kinetics of thrombin
generated at a particular point in time (25). Thrombin is the
key enzyme of the coagulation cascade, which is generated
following factor X activation. The generation of thrombin
controls, among other functions, the amount of fibrin generated
and thus triggers a stable clot (26). The TG measures the
cleavage of a fluorogenic substrate over time, resulting in a
characteristic curve describing the thrombin generation activity.
The parameters of the TG are retrieved from this curve: the
maximum concentration of thrombin (thrombin peak height),
the total amount of thrombin generation (area under the curve;
AUC), and the time to initiation of the exponential phase (lag
time). Following these considerations, one might hypothesize
that TG is an elegant, functional assay to be used to monitor
DOAC, including the anti-Xa inhibitors rivaroxaban, apixaban,
and edoxaban. A strong correlation of TG measures with
anticoagulant drug concentrations would be a strong argument
for a potential application in monitoring DOAC.
Aims
We aimed to study the association of state-of-the-art thrombin
generation measurements with rivaroxaban, apixaban, and
edoxaban drug concentrations, and compare the results with the
performance of an anti-Xa assay in a prospective multicenter
cross-sectional study conducted in routine clinical practice.
METHODS
Design, Setting, and Population
This is a multicenter cross-sectional study conducted between
2018 and 2019 (20). Patients treated with rivaroxaban, apixaban,
or edoxaban in routine clinical practice were included in
nine specialized hemostasis laboratories affiliated to tertiary
hospitals in Switzerland. Inclusion criteria were (a) age above
18 years, (b) use of rivaroxaban, apixaban, and edoxaban,
(c) DOAC drug level requested by the treating physician,
and (d) signed general informed consent, if requested by the
local authorities. Exclusion criteria were (a) refused general
informed consent, (b) use of heparin, (c) preanalytical issues,
(d) intake of more than one DOAC, and (e) insufficient sample
material. To cover the full range of drug levels observed
in clinical practice, we collected samples regardless of the
time of last drug intake. The study design is illustrated in
Figure 1 (CONSORT flow diagram). Ultra-performance liquid
chromatography-tandem mass spectrometry (LC-MS/MS) was
used as reference (gold) standard because it is regarded as the
most accurate technique to measure DOAC drug concentrations
(27). The study was approved by the appropriate ethical
committees and all participating institutions. The study was
conducted in accordance with the declaration of Helsinki.
Data Collection and Handling of Samples
Protocols were implemented at all participating institutions to
ensure adequate pre-analytic conditions (28). Blood samples
were drawn in plastic tubes containing 1mL trisodium citrate
(0.106mol L−1) per mL of blood. Samples were centrifuged using
an established scheme (28), and aliquots were immediately snap-
frozen at −20◦C and stored at −80◦C until shipment. Samples
were sent on dry ice to the central laboratory and delivered
within 3–4 h. Samples were kept frozen until the determination of
laboratory tests without any freeze-thaw cycles. All laboratory test
results were exported automatically to avoid any typing errors.
Coded clinical and laboratory data were stored in a secured
RedCAP database. The coding list was stored separately with
access by the principal investigator only. The following data were
collected: age, sex, and drug.
Thrombin Generation Measurements
An automated thrombin generation assay with high precision
characteristics was selected for this study. The Ceveron R©
TGA RC High (Technoclone, Vienna, Austria) was used on
a Ceveron R© t100 analyzer (Technoclone, Vienna, Austria),
and the manufacturer’s instructions were strictly followed. The
responsiveness of the Ceveron R© TGA RC High trigger reagent
for the measurement of direct oral anticoagulants was confirmed
in a previous study using spiked samples (29). All lyophilized
reagents and calibrators were brought to room temperature,
reconstituted with distilled water, and gently mixed. A 4-
point calibration curve was generated using the Ceveron R©
TGA CAL set (calibrated against the Thrombin Reference
Preparation of the WHO). Before each test run, internal quality
control was done using the Ceveron R© TGA CONT H and L
vials (lyophilized human plasma with increased or decreased
thrombin generation). Between-run impression was determined
by 19 runs with commercially available frozen normal human
plasma (Technoclone, Vienna, Austria). The samples were
thawed for 15min in a water bath at 37◦C and analyzed
immediately. To patient’s plasma (40 µL), Ceveron R© TGA BUF
(Tris-Hepes-NaCl buffer), Ceveron R© TGA RC High trigger
reagent (high concentration of phospholipid micelles containing
recombinant human tissue factor in Tris-Hepes-NaCl buffer),
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FIGURE 1 | Flow of the patients. A prospective, multicentre cross-sectional study was conducted to study the association of a state-of-the-art thrombin generation
assay with rivaroxaban, apixaban, and edoxaban drug concentrations in contrast to the association obtained with an anti-Xa assay.
TABLE 1 | Baseline characteristics of patients treated with rivaroxaban, apixaban or edoxaban (n = 559).
Patients treated with
Rivaroxaban Apixaban Edoxaban All Missing data
Patients (n/%) 300 (53.7) 220 (39.4) 39 (7.0) 559 (100) 0
Age (median/IQR) 73 (62–82) 78 (67–82) 75 (63–80) 75 (65–82) 91
Sex (n/%) 7
Male 173 (57.9) 128 (59.5) 22 (59.5) 323 (58.5) –
Female 126 (42.1) 87 (40.5) 16 (40.5) 229 (41.5) –
N, number; IQR, interquartile range.
Ceveron R© TGA SUB (fluorogenic substrate 1mM Z-G-G-R-
AMC), and 25mM CaCl2 were added to give 150 µL final
reaction mixture. Even though precise concentrations of tissue
factor and phospholipids are not given, tissue factor ranges
between 20 and 50 pM and phospholipids around 5µM. The
fluorescent substrate was monitored by the Ceveron R© t100
TG software, calculating thrombin generation over time. The
following parameters were used as readouts: (a) peak thrombin
generation (nmol); (b) the lag time (min); and (c) the area under
the curve (AUC; nmol∗min). Frozen normal human plasma was
analyzed in line with patients’ samples in each test run.
Determination of the Anti-Xa Activity
The TECHNOCHROM R© anti-Xa assay was used for
determining the anti-Xa activity, using rivaroxaban, apixaban,
and edoxaban calibrators (Technoclone, Vienna, Austria).
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TABLE 2 | Accuracy of anti-Xa measurements and thrombin generation results with regard to drug concentration in 559 patients taking rivaroxaban, apixaban, or
edoxaban in clinical practice.
Measurement Anti-Xa activity (µg L−1) Peak thrombin generation (nM) Area under the curve (nM × min) Lag time (min)
Spearman’s correlation coefficient (95% CI) 0.96 (0.95, 0.97) −0.72 (−0.77, −0.66) −0.55 (−0.61, −0.48) 0.80 (0.75, 0.84)
Deming regression slope (95% CI) 0.81 (0.73, 0.88) −0.72 (−0.95, −0.56) −15.89 (−19.04, −13.57) 0.01 (0.01, 0.02)
Y-intercept (95% CI) 13.8 (7.1, 20.4) 313.9 (292.5, 339.1) 4842.3 (4607.2, 5154.9) 3.9 (3.6, 4.1)
Bland-Altman difference plotBias (95% CI) 8.93 (3.71, 14.15) NA NA NA
Lower limit of agreement (95% CI) −86.86 (−95.90, −77.82) NA NA NA
Upper limit of agreement (95% CI) 104.72 (95.68, 113.76) NA NA NA
Ultra-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to determine drug levels. The Spearman’s correlation coefficient is given (rs), coefficients
of Deming regression, as well as measures of the Bland-Altman difference plot.
Measurements were done on a Ceveron R© t100 analyzer
(Technoclone, Vienna, Austria). Samples were thawed for 15min
in a water bath at 37◦C and analyzed immediately. For DOAC
concentrations ≤150 ng/mL, samples, calibrators, and controls
were assayed in a 1:5 dilution and for concentrations≥150 ng/mL
in a 1:20 dilution. The instructions of the manufacturer were
strictly followed. The kit consists of 20mL reagent 1 (anti-Xa
buffer, TRIS-EDTA buffer, pH 8.4), 4mL reagent 2 (Bovine
Factor Xa), and 4mL reagent 3 (Chromogenic substrate). All
reagents had reached room temperature before use, bovine
factor Xa, and the substrate was preheated to 37◦C. Reagent 2
and 3 were separately reconstituted in 4mL distilled water. The
following substances were incubated in a well of a microtiter
plate, incubated at 37◦C: 200 µL of the diluted sample, 200 µL of
bovine factor Xa (mixed and incubated at 37◦C for 60 s), 200 µL
of Xa substrate (mixed and incubated at 37◦C for 30 s), and 200
µL 2% citric acid (mixed and measured absorbance at 405 nm).
Determination of the LC-MS/MS
Rivaroxaban, apixaban, edoxaban, and edoxaban M4 were
quantified by LC-MS/MS as previously described (20). Briefly,
protein precipitation and analyte extraction were performed
by adding to the plasma acetonitrile:water 1:1 (v/v), extraction
buffer (MassTox TDM Series A, Chromsystems, Gräfelfing,
Germany), and precipitation reagent (MassTox TDM Series,
Chromsystems, Gräfelfing, Germany) containing the isotope
labeled internal standards (13C6 rivaroxaban, 13CD3 apixaban,
13CD2 edoxaban) The samples were vortexed and then
centrifuged at 14000 rcf and 20◦C for 4min. The supernatant was
diluted with water: methanol 8:2 (v/v) and stored at 10◦C until
analysis. Calibrators and QCs were prepared in pooled plasma.
Then, the extracted samples were analyzed by reversed-phase
chromatography on a triple quadrupole mass spectrometer (Xevo
TQ-S, Waters, Milford, USA) coupled to a UPLC Acquity I-Class
system (Waters, Milford, USA). EdoxabanM4 concentration was
summed up with edoxaban concentration for further analysis.
Statistical Analysis
The demographic characteristics were described using
proportions and percentages and a median and interquartile
range (IQR) for the continuous variables. The accuracy of the
TG assay and the anti-Xa assay was determined by calculating
Spearman’s correlation coefficient in relation to the plasma
concentration as measured by LC-MS/MS (overall and per
drug). A correlation coefficient of rs≥0.9 was considered as
accurate (alternative hypothesis). The Deming regression was
used to describe the linear relationship, and a Bland-Altman
plot was created to observe a potential bias over the spectrum
of measurements (done for the anti-Xa activity only) (30).
The systematic differences between the assay are analyzed by
calculating the mean difference and the SD to compute 95%
limits of agreement for every level of measurements (average
difference ± 1.96 standard deviation of the difference) (31). To
assess the diagnostic accuracy of the TG and the anti-Xa assay
in terms of clinical utility, we determined their sensitivity and
specificity with regard to the clinically relevant drug level 50
µg/L, used as a cut-off below which most invasive procedures
allowed. A sensitivity of at least 90% and a specificity of more
than 80% were regarded as adequate. All statistical analyses were
performed using RStudio (1.3. 1093-1); figures were created
using Prism 8 (GraphPad Software, Inc., La Jolla, CA, USA).
RESULTS
Patient Characteristics
Nine-hundred and thirty-two patients were included in this
prospective multicenter cross-sectional study; the CONSORT
flow diagram is given in Figure 1. From this population, 36
patients were excluded because of heparin use, five patients due
to pre-analytical issues, two patients because of using more than
one DOAC, and 330 patients due to insufficient sample material.
Eventually, samples of 559 patients were used for the current
analysis. Of those, 300 patients used rivaroxaban, 220 apixaban,
and 39 edoxaban. The median age was 75 years (IQR, 65–82
years) and 41.5% of the patients were female. Details are given
in Table 1.
Association Between Thrombin Generation
Measurements and Drug Concentrations
The association between thrombin generation measurements
and drug concentrations are illustrated in Figures 2B–D. The
correlation coefficient (rs) was −0.72 for peak thrombin
generation (95% confidence interval, CI, −0.77, −0.66), −0.55
for area under the curve (AUC; 95% CI −0.61, −0.48), and 0.80
for lag time (0.75, 0.84). The slope of the regression line was
−0.72 for peak thrombin generation (95% CI −0.95, −0.56),
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FIGURE 2 | Association of thrombin generation results and anti-Xa measurements with drug concentration in 559 patients taking rivaroxaban, apixaban, or edoxaban
in clinical practice (pooled data): (A) anti-Xa activity, (B) peak thrombin generation, (C) area under the curve (AUC), and (D) lag time. Ultra-high performance liquid
chromatography-tandem mass spectrometry (LC-MS/MS) was used to determine drug levels. The overall Spearman’s correlation coefficient (rs) was 0.96 in case of
anti-Xa measurements, −0.72 in case of peak thrombin generation, −0.55 in case of AUC, and 0.80 in case of lag time. A non-linear (smooth) curve is given to
illustrate the association.
−15.89 for AUC (−19.04, −13.57), and 0.01 for lag time (0.01,
0.02), see Table 2. The Y-intercept was 313.9 for peak thrombin
generation (95% CI 292.5, 339.1), 4842.3 for AUC (4607.2,
5154.9), and 3.9 for lag time (3.6, 4.1). Supplementary Table 1 of
the Supplemental Material reports the results for the individual
drugs. Determining the between-run imprecision (19 runs),
the coefficient of variation (CV) was 7.4% for peak thrombin
generation, 4.2% for AUC, and 7.1 % for lag time.
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FIGURE 3 | Distribution of thrombin generation results and anti-Xa measurements in patients with and without clinically relevant concentrations of rivaroxaban,
apixaban, and edoxaban (50 µg L−1): (A) anti-Xa activity, (B) peak thrombin generation, (C) area under the curve (AUC), and (D) lag time. *Thrombin generation
results are expressed in relation to measurements obtained with standardized human plasma (for example: AUC patients/AUC SHP). Ultra-high performance liquid
chromatography-tandem mass spectrometry (LC-MS/MS) was used to determine drug levels. The sensitivity was 83% (95% CI, 78, 87) in case of peak thrombin
generation (cut-off level was 80% of normal plasma), 61% (56, 66) in case of AUC (80% of normal plasma), 89% (85, 92) in case of lag time (120% of normal plasma),
and 95% in case of anti-Xa activity (95% CI, 92, 97). The specificity was 70% (95% CI, 64, 76) in case of peak thrombin generation, 78% (72, 83) in case of AUC, 66%
(60, 72) in case of lag time, and 92% in case of anti-Xa activity (95% CI, 88, 95).
Association Between Anti-Xa Activity and
Drug Concentrations
Figure 2A illustrates the association between anti-Xa activity and
drug concentrations. The correlation coefficient (rs) was 0.96
(95% CI 0.95–0.97). The slope of the regression line was 0.81
(95% CI 0.73, 0.88) and the Y-intercept was 13.8 (7.1, 20.4), see
Table 2. The bias of the Bland-Altman difference plot is 8.9 (95%
CI 3.7, 14.2) with a lower limit of agreement of −86.9 (−95.9,
−77.8) and upper limit of agreement of 104.7 (95.7, 113.8). See
Supplementary Figure 1 and Supplementary Table 1.
Diagnostic Accuracy Regarding Clinically
Significant Drug Levels
The distribution of measurements in patients with and
without clinically relevant drug levels (50 µgL−1) is shown in
Figure 3. Using 80% of peak thrombin generation measured
in standardized normal plasma as a cut-off, the sensitivity was
83% (95% CI, 78, 87), and the specificity was 70% (64, 76).
AUC measurements resulted in a sensitivity of 61% (95% CI,
56, 66) and a specificity of 78% (72, 83). Sensitivity of lag
time measurements at a cut-off of 120% of standardized normal
plasma was 89% (95% CI, 85, 92), and the specificity was 66%
(60, 72). In contrast, the sensitivity was 95% in case of anti-
Xa measurements (95% CI, 92, 97) and specificity was 92% (88,
95), respectively. Receiver-operating characteristics are given in
Figure 4.
As a sensitivity analysis, we used 50% of standardized normal
plasma as an additional cut-off. In this case, the sensitivity of
peak thrombin generation measurements was 49% (95% CI, 44,
55) and the specificity was 93% (90, 96). The sensitivity of AUC
measurements was 29% (95% CI, 24, 34) and the specificity 96%
(92, 98). For lag timemeasurements, the sensitivity was 64% (95%
CI, 58, 69) as a cut-off of 150% the standardized normal plasma,
and the specificity was 94% (90, 96).
DISCUSSION
This study reports 559 patients treated with rivaroxaban,
apixaban, or edoxaban in routine clinical practice, which were
studied in a cross-sectional study analyzing thrombin generation
assay and anti-Xa activity in comparison to LC-MS/MS. The
correlation of thrombin generation measurements with drug
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FIGURE 4 | Receiver operating characteristics (ROC) curve of thrombin
generation results and anti-Xa measurements for clinically relevant
concentrations of rivaroxaban, apixaban, and edoxaban (50 µg L−1). AUC was
0.98 for anti-Xa measurements, 0.85 for peak thrombin generation, 0.75 for
AUC, and 0.88 for lag time.
concentrations was weak, and clinically relevant drug levels were
not predicted correctly. In contrast, the correlation of anti-Xa
measurements with drug concentrations was high, and relevant
drug levels were predicted correctly.
Thrombin generation assay was conducted in the presence
of DOAC in a number of studies. Various in-vitro or ex-vivo
studies using spiked samples demonstrated that the presence
of DOAC changed TG measures (32–36). In particular, Khoo
et al. observed TG measures in 8 patient samples spiked with
dabigatran before and after adding activated prothromplex
concentrate (37). Bloemen et al. performed in-vitro and ex-
vivo measurements in 63 patients and studied the effect of
dabigatran in the presence and absence of idarucizumab (38).
Schenk et al. observed in 20 in-vitro and in-vivo patient samples
that rivaroxaban was significantly correlated with thrombin
generation parameters (39). Tripodi et al. observed in 20 samples
from healthy volunteers that apixaban affects all thrombin
generation parameters (40). Sinegre et al. observed a change
in TG parameters in 87 adult and 97 children patient samples
spiked in-vitro with edoxaban (41). Samama et al. demonstrated
concentration-dependent effects of edoxaban in spiked patient
samples (42). Similar results were also observed in a randomized,
placebo-controlled cross-over study including patients taking
rivaroxaban (43). Pfrepper et al. included 380 samples from
patients taking apixaban, dabigatran, edoxaban, or rivaroxaban
and correlated anti-Xa measurements with TG parameters (44).
Similar to these studies, we observed changes in TG measures
in patients treated with rivaroxaban, apixaban, and edoxaban.
However, correlation of TG parameters with drug concentrations
was weak to moderate only.
In contrast to previous studies, we included a large number
of patients taking rivaroxaban, apixaban, or edoxaban in clinical
practice. LC-MS/MS was conducted as a reference standard in
all patient samples. Besides, the sensitivity and specificity of
TG measurements were calculated against established cut-offs
levels. Anti-Xa activity was measured in parallel to compare the
results with an assay used routinely in most tertiary hospitals. In
addition, patients were recruited from nine tertiary hospitals in
Switzerland, which increases the external validity and makes the
samples more representative for the general patient population.
Therefore, selection bias is considered to be unlikely (45).
However, several limitations must be noted. First and most
important, we did not record clinical outcomes in terms of
bleedings and thromboembolic events. As long as these events
are rare, a study like this would need a much larger patient
population and a very long observation period. Second, the
number of patients is limited in certain subgroups such as lower
concentrations of edoxaban. Even though there is no indication
that the effects observed might be different in these subgroups,
we cannot fully exclude such an effect. Third, our results were
obtained with one specific TG device and reagent and the
results might be different with other analyzers. However, this
is a device of the latest generation with a high precision and
there is no hint that this assay could perform worse than others.
Fourth, thrombin generation measurements were conducted
using frozen citrated samples, and we cannot entirely exclude that
the results might be different in whole blood or fresh samples.
However, all pre-analytical requirements were strictly addressed,
and we do not believe that this might have entirely changed
the results.
Following our data, we have to reject the hypothesis that TG
measurements adequately reflect DOAC drug concentrations.
The association of thrombin generation measurements with
drug concentrations was weak, and clinically relevant drug
levels were not predicted correctly. We consider our data to
be robust because they were obtained in the most accurate
study conducted so far. Therefore, our results represent a clear
argument against a potential application of TG in monitoring
DOAC. One might argue that TG unfolds its utility for
monitoring DOAC by assessing the biological efficacy rather than
the drug concentration. Several central arguments can be raised
supporting this proposition: First, TG reflects the mechanism
of thrombus formation more than any other laboratory test
(discussed above). Secondly, TG measurements vary among
patients with similar drug levels, potentially reflecting different
degrees of baseline pro-thrombotic tendency (4). Thirdly,
anticoagulant treatment at a given dosage is not effective in
some clinical settings representing high-risk pro-thrombotic
situations [e.g., DOAC in patients with antiphospholipid
antibody syndrome (46); vitamin K-antagonists in cancer
patients (47)]. However, this claim must be supported with data
demonstrating a relevant association between TG measurements
and clinical outcomes in terms of thromboembolic or bleeding
events in anticoagulated patients. To the best of our knowledge,
these data are not (yet) available. In contrast, the correlation
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between anti-Xa activity and drug concentrations was strong in
our study as well as in others, and an association between anti-Xa
activity and clinical outcomes have been shown in various clinical
settings (5–7, 48–50).
CONCLUSION
We report results of a large prospective study including
patients treated with rivaroxaban, apixaban, or edoxaban in
routine clinical practice. The correlation of thrombin generation
measurements with DOAC drug concentrations was weak, and
clinically relevant drug levels were not predicted correctly. Our
results do not support an application of TG in the monitoring
of DOAC.
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